Device
BSS
BSS is a medical device with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DEVICE
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
2
50%
Ph phase_4
2
50%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 4Post-market surveillance
2(50.0%)
N/ANon-phased studies
2(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Other(1)
Detailed Status
Completed3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 42 (50.0%)
N/A2 (50.0%)
Trials by Status
completed375%
unknown125%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_4
The Evaluation of Balanced Salt Solution During Cataract Surgery
NCT05853978
completednot_applicable
Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings
NCT03751033
unknownnot_applicable
Corneal Protect Used During Cataract Surgery
NCT02363530
completedphase_4
Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery
NCT00818844
Clinical Trials (4)
Showing 4 of 4 trials
NCT05853978Phase 4
The Evaluation of Balanced Salt Solution During Cataract Surgery
NCT03751033Not Applicable
Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings
NCT02363530Not Applicable
Corneal Protect Used During Cataract Surgery
NCT00818844Phase 4
Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery
All 4 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 4